Analyst firms · Barclays · VTRS

Barclays VTRS price target and rating history

Viatris Inc. (VTRS) · Health Care

Barclays rates Viatris Inc. (VTRS) Overweight with a $15 price target, as of its latest action on Dec 9, 2025. It has published 3 rating actions on VTRS since April 2023, including 0 upgrades and 2 downgrades. Across 5 firms with a VTRS price target in the last 12 months, the median target is $18. Barclays's $15 is 17% below that.

Current rating
Overweight
Price target
$15
Median target, all firms
$18
Actions on VTRS
3

Barclays price target on VTRS

$15$13$11202420252026
Barclays price target on VTRS, each point a stated target, April 2023 to December 2025.

Every Barclays rating on VTRS

How other firms rate VTRS

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
OppenheimerOutperform$25Sep 23, 2026
Leerink PartnersOutperform$20Sep 9, 2026
UBSBuy$18Feb 9, 2026
Argus ResearchBuy$15Jan 16, 2026
BarclaysOverweight$15Dec 9, 2025

Questions about Barclays and VTRS

What is Barclays's price target for VTRS?
Barclays's latest stated price target for Viatris Inc. (VTRS) is $15, from its action on Dec 9, 2025.
What is Barclays's rating on VTRS?
Barclays rates VTRS Overweight, a bullish rating, as of Dec 9, 2025.
When did Barclays last change its view on VTRS?
On Dec 9, 2025, Barclays starts coverage at Overweight, price target $15.
How does Barclays's VTRS target compare with other analysts?
Across 5 firms with a VTRS price target in the last 12 months, the median target is $18. Barclays's $15 is 17% below that.

More VTRS rating histories

All Barclays ratingsVTRS news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.